brolamfetamine   Click here for help

GtoPdb Ligand ID: 163

Abbreviated name: DOB
Synonyms: 2,5-dimethoxy-4-bromoamphetamine
Compound class: Synthetic organic
Comment: The INN-assigned compound brolamfetamine is a racemic mixture of two enantiomers. The structure shown here does not specify stereochemistry and represents the mixture.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 1
Hydrogen bond donors 1
Rotatable bonds 4
Topological polar surface area 44.48
Molecular weight 273.04
XLogP 2.39
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES COc1cc(Br)c(cc1CC(N)C)OC
Isomeric SMILES COc1cc(Br)c(cc1CC(N)C)OC
InChI InChI=1S/C11H16BrNO2/c1-7(13)4-8-5-11(15-3)9(12)6-10(8)14-2/h5-7H,4,13H2,1-3H3
InChI Key FXMWUTGUCAKGQL-UHFFFAOYSA-N
References
1. Egan C, Grinde E, Dupre A, Roth BL, Hake M, Teitler M, Herrick-Davis K. (2000)
Agonist high and low affinity state ratios predict drug intrinsic activity and a revised ternary complex mechanism at serotonin 5-HT(2A) and 5-HT(2C) receptors.
Synapse, 35: 144-150. [PMID:10611640]
2. Egan CT, Herrick-Davis K, Teitler M. (1998)
Creation of a constitutively activated state of the 5-hydroxytryptamine2A receptor by site-directed mutagenesis: inverse agonist activity of antipsychotic drugs.
J Pharmacol Exp Ther, 286 (1): 85-90. [PMID:9655845]
3. Herrick-Davis K, Egan C, Teitler M. (1997)
Activating mutations of the serotonin 5-HT2C receptor.
J Neurochem, 69 (3): 1138-44. [PMID:9282936]
4. Knight AR, Misra A, Quirk K, Benwell K, Revell D, Kennett G, Bickerdike M. (2004)
Pharmacological characterisation of the agonist radioligand binding site of 5-HT(2A), 5-HT(2B) and 5-HT(2C) receptors.
Naunyn Schmiedebergs Arch Pharmacol, 370 (2): 114-23. [PMID:15322733]
5. Nelson DL, Lucaites VL, Wainscott DB, Glennon RA. (1999)
Comparisons of hallucinogenic phenylisopropylamine binding affinities at cloned human 5-HT2A, -HT(2B) and 5-HT2C receptors.
Naunyn Schmiedebergs Arch Pharmacol, 359 (1): 1-6. [PMID:9933142]